Učitavanje...
Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants
Human immunodeficiency virus type 1 (HIV-1) entry is an attractive target for therapeutic intervention. Two drugs that inhibit this process have been approved: the fusion inhibitor T20 (enfuvirtide [Fuzeon]) and, more recently, the CCR5 blocker maraviroc (Selzentry). T1249 is a second-generation fus...
Spremljeno u:
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Microbiology (ASM)
2008
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2447091/ https://ncbi.nlm.nih.gov/pubmed/18434391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00352-08 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|